Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism

NCT04833192 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2022-04-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the serum dehydroepiandrosterone sulfate in subclinical hypercortisolism

Conditions

  • Adrenal Incidentaloma
  • Subclinical Hypercortisolism

Interventions

DIAGNOSTIC_TEST

experimental group

DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-04-01
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833192 on ClinicalTrials.gov